Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, Zhang W, Li Y, Li R. Neutrophil-to-lymphocyte ratio: An effective predictor of corticosteroid response in IgA nephropathy. Int Immunopharmacol. 2019;74:105678.

Article  CAS  PubMed  Google Scholar 

Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35(1):157–65.

Article  CAS  PubMed  Google Scholar 

Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract. 2009;63(6):880–8.

Article  CAS  PubMed  Google Scholar 

Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int. 2012;82(8):840–56.

Article  PubMed  Google Scholar 

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the testing randomized clinical trial. JAMA. 2017;318(5):432–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–14.

Article  CAS  PubMed  Google Scholar 

Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019;19(1):288.

Article  PubMed  PubMed Central  Google Scholar 

Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Suda K, et al. Prognostic impact of change in the fibrinogen and albumin score during preoperative treatment in esophageal cancer patients. World J Surg. 2017;41(11):2788–95.

Article  PubMed  Google Scholar 

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–63.

Article  CAS  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

Article  PubMed  PubMed Central  Google Scholar 

Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.

Article  Google Scholar 

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–21.

Article  PubMed  Google Scholar 

Bi TD, Zheng JN, Zhang JX, Yang LS, Liu N, Yao L, et al. Serum complement C4 is an important prognostic factor for IgA nephropathy: a retrospective study. BMC Nephrol. 2019;20(1):244.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014;9(3):484–9.

Article  PubMed  PubMed Central  Google Scholar 

Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS ONE. 2012;7(6):e38904.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021, 100(4S): S1-S276.

Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694–701.

Article  CAS  PubMed  Google Scholar 

Hao Y, Zhao Y, Huang R, Fu P. Analysis of the relationship between Oxford classification, IgM deposition and multiple indexes and the adverse prognosis of patients with primary IgA nephropathy and related risk factors. Exp Ther Med. 2019;17(2):1234–9.

CAS  PubMed  Google Scholar 

Liu D, You J, Liu Y, Tang X, Tan X, Xia M, et al. Serum immunoglobulin G provides early risk prediction in immunoglobulin a nephropathy. Int Immunopharmacol. 2019;66:13–8.

Article  CAS  PubMed  Google Scholar 

Wang Y, Hu Z, Wu J, Wang P, Yang Q, Li Y, et al. High renal DC-SIGN(+) cell density is associated with severe renal lesions and poor prognosis in patients with immunoglobulin a nephropathy. Histopathology. 2019;74(5):744–58.

Article  PubMed  Google Scholar 

Xia FY, Zhu L, Xu C, Wu QQ, Chen WJ, Zeng R, et al. Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy. Nutr Metab. 2019;16:2.

Article  Google Scholar 

Yuan Y, Wang Q, Ni Z, Che X, Cao L, Shao X, et al. Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study. J Transl Med. 2015;13:186.

Article  PubMed  PubMed Central  Google Scholar 

Ni Z, Yuan Y, Wang Q, Cao L, Che X, Zhang M, et al. Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission. J Transl Med. 2014;12:194.

Article  PubMed  PubMed Central  Google Scholar 

Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479–85.

Article  CAS  PubMed  Google Scholar 

Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M, et al. The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol. 2013;17(4):555–62.

Article  CAS  PubMed  Google Scholar 

Obata J, Tanaka N, Mizuno R, Kanao K, Mikami S, Matsumoto K, et al. Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma. BJU Int. 2016;118(4):598–603.

Article  CAS  PubMed  Google Scholar 

Cai H, Zhang ZH, Zhou YJ, Liu J, Chen HQ, Lin RY. The prognostic value of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma. Ear Nose Throat J. 2020;100:145561320920746.

Google Scholar 

Pan M, Zhang J, You X, Li D, Lv Y, Zhang J, et al. Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study. Hum Pathol. 2018;75:47–54.

Article  CAS  PubMed  Google Scholar 

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36.

Article  CAS  PubMed  Google Scholar 

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044–52.

Article  CAS  PubMed  Google Scholar 

Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29(1):317–25.

Article  CAS  PubMed  Google Scholar 

Huang X, Xu G. An update on targeted treatment of IgA nephropathy: an autoimmune perspective. Front Pharmacol. 2021;12:715253.

Article  CAS  PubMed  PubMed Central  Google Scholar